ICU Medical Announces Third Quarter 2025 Results and Updates its Fiscal Year 2025 Guidance

Rhea-AI Summary

ICU Medical (Nasdaq:ICUI) reported third quarter 2025 results and raised FY2025 guidance on Nov 6, 2025. Q3 revenue was $537.0M versus $589.1M year-ago; GAAP gross profit was $200.9M and gross margin improved to 37% from 35%.

GAAP net loss narrowed to $(3.4)M (loss of $(0.14) per diluted share); adjusted diluted EPS was $2.03 (prior year $1.59) and adjusted EBITDA was $105.9M (prior year $94.8M). Company updated FY2025 guidance: GAAP net loss range to $(8)M–$0M, adjusted EBITDA to $395M–$405M, and diluted EPS to $7.35–$7.65.

Positive

• Adjusted diluted EPS of $2.03 in Q3 2025
• Adjusted EBITDA of $105.9M in Q3 2025
• FY2025 adjusted EBITDA guidance raised to $395M–$405M
• FY2025 diluted EPS guidance increased to $7.35–$7.65
• GAAP gross margin improved to 37% in Q3 2025

Negative

• Q3 revenue declined to $537.0M from $589.1M (≈8.9%)
• Vital Care product line down $86.5M in Q3 due to IV Solutions disposal
• Nine-month revenue declined by $61.7M to $1,690.5M
• Company reported a GAAP net loss of $(3.4)M in Q3 2025

Insights

Senior Corporate Finance Analyst

ICU Medical reports mixed Q3 results but materially stronger guidance and improved adjusted profitability.

Revenue fell to $537.0 million from $589.1 million year‑over‑year, driven largely by the disposal of the IV Solutions business within the Vital Care line; Consumables and Infusion Systems grew. GAAP gross margin expanded to 37% from 35%, GAAP net loss narrowed to $(3.4) million from $(33.0) million, and adjusted metrics improved: adjusted diluted EPS rose to $2.03 and Adjusted EBITDA to $105.9 million.

Management materially tightened fiscal outlook for fiscal 2025, moving GAAP net loss guidance to $(8) million to $0 million and raising adjusted EBITDA to $395 million–$405 million and adjusted diluted EPS to $7.35–$7.65. The improved guidance aligns with stronger adjusted profitability but rests on non‑GAAP reconciliations and the one‑time effect of the IV Solutions disposal; watch the company’s reconciliations and the cadence of cash flow conversion over the remainder of fiscal 2025.

SAN CLEMENTE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended September 30, 2025.

Third Quarter 2025 Results

Third quarter 2025 revenue was $537.0 million, as compared to $589.1 million in the same period in the prior year. GAAP gross profit for the third quarter of 2025 was $200.9 million, as compared to $204.9 million in the same period in the prior year. GAAP gross margin for the third quarter of 2025 was 37%, as compared to 35% in the same period in the prior year. GAAP net loss for the third quarter of 2025 was $(3.4) million, or $(0.14) per diluted share, as compared to GAAP net loss of $(33.0) million, or $(1.35) per diluted share, for the third quarter of 2024. Adjusted diluted earnings per share for the third quarter of 2025 was $2.03 as compared to $1.59 for the third quarter of 2024. Adjusted EBITDA was $105.9 million for the third quarter of 2025 as compared to $94.8 million for the third quarter of 2024.

Adjusted EBITDA and adjusted diluted earnings per share are measures calculated and presented on the basis of methodologies other than in accordance with GAAP. Please refer to the Use of Non-GAAP Financial Information following the financial statements herein for further discussion and reconciliations of these measures to GAAP measures.

Vivek Jain, ICU Medical’s Chief Executive Officer, said, “We are pleased with our third quarter results."

Revenues by product line for the three and nine months ended September 30, 2025 and 2024 were as follows (in millions):

		Three months ended September 30,									Nine months ended September 30,
Product Line		2025			2024			$ Change			2025			2024			$ Change
Consumables		$	285.1		$	264.9		$	20.2		$	824.4		$	770.7		$	53.7
Infusion Systems			173.9			159.8			14.1			507.9			480.7			27.2
Vital Care*			78.0			164.5			(86.5)			358.2			500.8			(142.6)
Total**		$	537.0		$	589.2		$	(52.2)		$	1,690.5		$	1,752.2		$	(61.7)

^{*On May 1, 2025, we disposed of our IV Solutions business which was included within our Vital Care product line. For the three and nine months ended September 30, 2025, Vital Care includes $0.0 million and $126.5 million of IV Solutions revenue, respectively, as compared to $88.0 million and $268.7 million for the three and nine months ended September 30, 2024, respectively.
**Totals may differ from the income statement due to the rounding of product lines.}

Fiscal Year 2025 Guidance

For Fiscal Year 2025 the Company is updating its estimates of GAAP net loss from a range of $(43) million to $(35) million to a range of $(8) million to $0 million and GAAP diluted loss per share from a range of $(1.68) to $(1.38) to a range of $(0.30) to $0.00. The Company is updating the estimate of the range of its full year 2025 guidance of adjusted EBITDA from a range of $380 million to $390 million to a range of $395 million to $405 million and diluted earnings per share from a range of $6.85 to $7.15 to a range of $7.35 to $7.65.

Conference Call

The Company will host a conference call to discuss its third quarter 2025 financial results, today at 4:30 p.m. ET (1:30 p.m. PT). The call can be accessed at (800) 267-6316, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's website at www.icumed.com, clicking on the Investors tab, clicking on Event Calendar and clicking on the Webcast icon and following the prompts. The webcast will also be available by replay.

About ICU Medical

ICU Medical (Nasdaq: ICUI) is a global leader in infusion systems, infusion consumables and high-value critical care products used in hospital, alternate site and home care settings. Our team is focused on providing quality, innovation and value to our clinical customers worldwide. ICU Medical is headquartered in San Clemente, California. More information about ICU Medical can be found at www.icumed.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as “aim,” “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” or the negative thereof or comparable terminology and may include (without limitation) information regarding the Company's expectations, goals and intentions regarding the future and financial outlook for 2025. These forward-looking statements are based on management's current expectations, estimates, forecasts and projections about the Company and assumptions management believes are reasonable, all of which are subject to risks and uncertainties that could cause actual results and events to differ materially from those stated in the forward-looking statements. These risks and uncertainties include, but are not limited to: risks from doing business in foreign countries, including related to tariffs and other barriers to trade; the Company’s ability to compete successfully, including with larger international companies and established local companies; decreased demand for the Company's products; costs related to product development; cost volatility or potential loss of supply of raw materials due to our dependence on single and limited source third-party suppliers; ability to achieve operating efficiencies; risks related to significant sales through our distributors; inflation and foreign currency exchange rates; impacts from global macroeconomic and geopolitical conditions; healthcare costs and reimbursement levels; disruptions at the FDA and other governmental agencies; damage at the Company’s manufacturing or supply facilities; risks associated with the IV Solutions joint venture and the Smiths Medical acquisition; risks associated with the timing and resolution of the 2025 warning letter; risks related to protection of our information technology systems and compliance with privacy laws and regulations; risks related to our intellectual property; and the other important factors described under “Risk Factors” in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and our subsequent filings with the SEC, including, without limitation, in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025. Forward-looking statements contained in this press release are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise unless required by law.

ICU MEDICAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except par values)
		September 30, 2025 (Unaudited)			December 31, 2024
ASSETS
CURRENT ASSETS:
Cash and cash equivalents		$	299,732		$	308,566
Accounts receivable, net of allowance for doubtful accounts			191,541			182,828
Inventories			622,443			584,676
Prepaid expenses and other current assets			93,574			81,531
Assets held for sale			—			284,382
TOTAL CURRENT ASSETS			1,207,290			1,441,983
PROPERTY, PLANT AND EQUIPMENT, net			455,967			442,746
OPERATING LEASE RIGHT-OF-USE ASSETS			56,598			53,295
GOODWILL			1,498,767			1,432,772
INTANGIBLE ASSETS, net			664,827			740,789
DEFERRED INCOME TAXES			23,976			24,211
OTHER ASSETS			61,385			65,097
INVESTMENTS IN UNCONSOLIDATED AFFILIATES			134,086			3,038
TOTAL ASSETS		$	4,102,896		$	4,203,931
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable		$	171,752		$	148,020
Accrued liabilities			316,103			306,923
Current portion of long-term debt			—			51,000
Income tax payable			5,045			17,328
Liabilities held for sale			—			32,911
TOTAL CURRENT LIABILITIES			492,900			556,182
LONG-TERM DEBT			1,313,931			1,531,858
OTHER LONG-TERM LIABILITIES			93,558			66,745
DEFERRED INCOME TAXES			41,371			48,814
INCOME TAX LIABILITY			33,886			35,097
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS’ EQUITY:
Convertible preferred stock, $1.00 par value; Authorized — 500 shares; Issued and outstanding — none			—			—
Common stock, $0.10 par value; Authorized — 80,000 shares; Issued — 24,686 shares at September 30, 2025 and 24,518 shares at December 31, 2024; and outstanding — 24,686 shares at September 30, 2025 and 24,517 shares at December 31, 2024			2,469			2,452
Additional paid-in capital			1,451,146			1,412,118
Treasury stock, at cost			(12)			(92)
Retained earnings			706,624			690,158
Accumulated other comprehensive loss			(32,977)			(139,401)
TOTAL STOCKHOLDERS' EQUITY			2,127,250			1,965,235
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY		$	4,102,896		$	4,203,931

ICU MEDICAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (In thousands, except per share data)
		Three months ended September 30,						Nine months ended September 30,
		2025			2024			2025			2024
TOTAL REVENUES		$	536,990		$	589,131		$	1,690,558		$	1,752,241
COST OF GOODS SOLD			336,109			384,279			1,071,504			1,154,717
GROSS PROFIT			200,881			204,852			619,054			597,524
OPERATING EXPENSES:
Selling, general and administrative			152,773			162,707			469,398			479,913
Research and development			21,251			21,028			66,409			66,260
Restructuring, strategic transaction and integration			13,138			16,828			46,053			50,069
Change in fair value of contingent earn-out			—			(3,947)			—			(3,991)
TOTAL OPERATING EXPENSES			187,162			196,616			581,860			592,251
INCOME FROM OPERATIONS			13,719			8,236			37,194			5,273
INTEREST EXPENSE, net			(19,808)			(24,683)			(62,388)			(72,296)
OTHER INCOME (EXPENSE), net			607			(1,481)			662			(7,206)
GAIN ON SALE OF BUSINESS			2,969			—			44,792			—
(LOSS) INCOME BEFORE INCOME TAXES AND EQUITY IN (LOSS) EARNINGS OF UNCONSOLIDATED AFFILIATES			(2,513)			(17,928)			20,260			(74,229)
BENEFIT (PROVISION) FOR INCOME TAXES			658			(15,055)			(5,090)			(19,631)
NET (LOSS) INCOME FROM CONSOLIDATED COMPANIES			(1,855)			(32,983)			15,170			(93,860)
EQUITY IN (LOSS) EARNINGS OF UNCONSOLIDATED AFFILIATES			(1,541)			—			1,296			—
NET (LOSS) INCOME		$	(3,396)		$	(32,983)		$	16,466		$	(93,860)
NET (LOSS) INCOME PER SHARE
Basic		$	(0.14)		$	(1.35)		$	0.67		$	(3.85)
Diluted		$	(0.14)		$	(1.35)		$	0.66		$	(3.85)
WEIGHTED AVERAGE NUMBER OF SHARES
Basic			24,686			24,438			24,624			24,353
Diluted			24,686			24,438			24,783			24,353

ICU MEDICAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (In thousands)
		Nine months ended September 30,
		2025			2024
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)		$	16,466		$	(93,860)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization			149,912			166,519
Noncash lease expense			13,739			16,008
Stock compensation			41,879			34,366
Loss on disposal of property, plant and equipment and other assets			3,211			184
Undistributed equity in earnings of unconsolidated affiliates			(1,296)			—
Debt issuance costs amortization			5,112			5,111
Change in fair value of contingent earn-out liability			—			(3,991)
Net gain on sale of business			(44,792)			—
Other			18,217			24,403
Changes in operating assets and liabilities, net of amounts acquired:
Accounts receivable			3,943			(11,517)
Inventories			(36,213)			9,416
Prepaid expenses and other current assets			(4,721)			(11,188)
Other assets			(7,149)			(17,540)
Accounts payable			23,328			21,086
Accrued liabilities			(28,887)			20,484
Income taxes, including excess tax benefits and deferred income taxes			(33,501)			4,360
Net cash provided by operating activities			119,248			163,841
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property, plant and equipment			(63,397)			(55,292)
Proceeds from sale of business			211,185			—
Proceeds from sale of assets			42			695
Intangible asset additions			(7,210)			(8,317)
Proceeds from sale and maturities of investment securities			—			500
Net cash provided by (used in) investing activities			140,620			(62,414)
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal repayments of long-term debt			(272,750)			(38,250)
Proceeds from exercise of stock options			5,972			5,883
Payments on finance leases			(1,543)			(775)
Payments of contingent earn-out liability			—			(2,600)
Tax withholding payments related to net share settlement of equity awards			(8,719)			(11,867)
Net cash used in financing activities			(277,040)			(47,609)
Effect of exchange rate changes on cash			8,338			4,472
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS			(8,834)			58,290
CASH AND CASH EQUIVALENTS, beginning of period			308,566			254,222
CASH AND CASH EQUIVALENTS, end of period		$	299,732		$	312,512

Use of Non-GAAP Financial Information

This press release contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles ("GAAP"). The non-GAAP financial measures should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. There are material limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may not be comparable to similarly titled non-GAAP financial measures used by other companies, including peer companies. Our management believes that the non-GAAP data provides useful supplemental information to management and investors regarding our performance and facilitates a more meaningful comparison of results of operations between current and prior periods. We use non-GAAP financial measures in addition to and in conjunction with GAAP financial measures to analyze and assess the overall performance of our business, in making financial, operating and planning decisions, and in determining executive incentive compensation.

The non-GAAP financial measures as shown in the tables below, exclude special items because they are highly variable or unusual and impact year-over-year comparisons.

For the three months ended September 30, 2025 and 2024, special items include the following:

Contract manufacturing: We manufacture certain products or product components in accordance with manufacturing services agreements. We do not include the contract revenue in our adjusted revenue, or any gross profit impact in our adjusted gross profit as the commercial relationship under these types of agreements are originally negotiated contemporaneously with a business combination or other transactions and are not indicative of normal market transactions.

Stock compensation expense: Stock-based compensation is generally fixed at the time the stock-based instrument is granted and amortized over a period of several years. The value of stock options is determined using a complex formula that incorporates factors, such as market volatility, that are beyond our control. The value of our restricted stock awards is determined using the grant date stock price, which may not be indicative of our operational performance over the expense period. Additionally, in order to establish the fair value of performance-based stock awards, which are currently an element of our ongoing stock-based compensation, we are required to apply judgment to estimate the probability of the extent to which performance objectives will be achieved. Based on the above factors, we believe it is useful to exclude stock-based compensation in order to better understand our operating performance.

Intangible asset amortization expense: We do not acquire businesses or capitalize certain patent costs on a predictable cycle. The amount of purchase price allocated to intangible assets and the term of amortization can vary significantly and are unique to each acquisition. Capitalized patent costs can vary significantly based on our current level of development activities. We believe that excluding amortization of intangible assets provides the users of our financial statements with a consistent basis for comparison across accounting periods.

Restructuring, strategic transaction and integration: We incur restructuring and strategic transaction charges that result from events, which arise from unforeseen circumstances and/or often occur outside of the ordinary course of our ongoing business. Although these events are reflected in our GAAP financial statements, these unique transactions may limit the comparability of our ongoing operations with prior and future periods.

Settlements: Occasionally, we are involved in contract renegotiations/legal settlements and other judgments that may result in one-time settlements. We exclude these settlements as they have no direct correlation to the operation of our ongoing business.

Change in fair value of contingent earn-out: We exclude the impact of certain amounts recorded in connection with business combinations. We exclude items that are either non-cash or not normal, recurring operating expenses due to their nature, variability of amounts, and lack of predictability as to occurrence and/or timing.

Quality system and product-related remediation: We exclude certain quality system and product-related remediation charges in determining our non-GAAP financial measures as they may limit the comparability of our ongoing operations with prior and future periods and distort the evaluation of our normal operating performance.

Gain on sale of business: We exclude any non-cash gains/losses on the sale of a business in determining our non-GAAP financial measures as the inclusion may limit the comparability of our ongoing operations with prior and future periods and distort the evaluation of our normal operating performance.

Noncash release of loss on contract provision: We provide certain services under fixed priced arrangements in accordance with a transition services arrangement. We do not include the loss on contract provision or subsequent provision release net of the related interest accretion as a result of providing those services in our non-GAAP financial measures as the agreement was negotiated contemporaneously with a disposition and is not indicative of a normal market transaction. The loss provision and subsequent release is a non-recurring noncash adjustment that if included may limit the comparability of our ongoing operations with prior and future periods.

From time to time in the future, there may be other items that we may exclude if we believe that doing so is consistent with the goal of providing useful information to investors and management.

In addition to the above special items, Adjusted EBITDA additionally excludes the following items from net income:

Depreciation expense: We exclude depreciation expense in deriving adjusted EBITDA because companies utilize productive assets of different ages and the depreciable lives can vary significantly resulting in considerable variability in depreciation expense among companies.

Interest, net: We exclude interest in deriving adjusted EBITDA as interest can vary significantly among companies depending on a company's level of income generating instruments and/or level of debt.

Taxes: We exclude taxes in deriving adjusted EBITDA as taxes are deemed to be non-core to the business and may limit the comparability of our ongoing operations with prior and future periods and distort the evaluation of our normal operating performance.

Adjusted Diluted EPS excludes from diluted EPS, net of tax, the special items listed above. The tax effect on the special items is calculated using the specific tax rate applied to each adjustment based on the nature of the item/or the tax jurisdiction in which the item has been recorded. Additionally, adjusted diluted EPS may exclude the income tax impact of certain non-recurring discrete tax items that are not reflective of income tax expense/benefit incurred as a result of current period earnings/ loss, as well as the impact of certain deferred tax valuation allowances when assessed against non-GAAP profitability.

We also present Free cash flow as a non-GAAP financial measure as management believes that this is an important measure for use in evaluating overall company financial performance as it measures our ability to generate additional cash flow from business operations. Free cash flow should be considered in addition to, rather than as a substitute for, net income as a measure of our performance or net cash provided by operating activities as a measure of our liquidity. Additionally, our definition of free cash flow is limited and does not represent residual cash flows available for discretionary expenditures due to the fact that the measure does not deduct the payments required for debt service and other obligations or payments made for business acquisitions. Therefore, we believe it is important to view free cash flow as supplemental to our entire statement of cash flows.

The following tables reconcile our non-GAAP financial measures for the periods presented:

ICU MEDICAL, INC. AND SUBSIDIARIES Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) (In thousands, except per share data)
		Adjusted EBITDA
		Three months ended September 30,
		2025			2024
GAAP net loss		$	(3,396)		$	(32,983)
Non-GAAP adjustments:
Interest, net			19,808			24,683
Stock compensation expense			15,243			11,770
Depreciation and amortization expense			50,802			55,675
Restructuring, strategic transaction and integration			13,138			16,828
Change in fair value of contingent earn-out			—			(3,947)
Quality system and product-related charges			13,797			7,737
Settlements			1,426			20
Gain on sale of business			(2,969)			—
Noncash release of loss on contract provision			(1,076)			—
Gross profit on contract manufacturing			(204)			—
(Benefit) provision for income taxes			(658)			15,055
Total non-GAAP adjustments			109,307			127,821
Adjusted EBITDA		$	105,911		$	94,838

ICU MEDICAL, INC. AND SUBSIDIARIES Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) (In thousands, except percentages and per share)
The Company’s U.S. GAAP results for the three months ended September 30, 2025 included special items which impacted the U.S. GAAP measures as follows:
	Total revenues		Gross profit		Selling, general and administrative		Research and development		Restructuring, strategic transaction and integration		Income (loss) from operations		Interest expense, net		Gain on sale of business		Income (loss) before income taxes and equity in earnings of unconsolidated affiliates		Benefit (provision) for income taxes		Net (loss) income from consolidated companies		Equity in (loss) earnings of unconsolidated affiliated		Net (loss) income		Diluted (loss) earnings per share
Reported (GAAP)	$	536,990	$	200,881	$	152,773	$	21,251	$	13,138	$	13,719	$	(19,808)	$	2,969	$	(2,513)	$	658	$	(1,855)	$	(1,541)	$	(3,396)	$	(0.14)
Reported percent of total revenues or (percent of income (loss) before income taxes and equity in earnings of unconsolidated affiliates)				37%		28%		4%		2%		3%	(4)%			1%		—%		26.2%		—%
Contract manufacturing		(3,695)		(204)		—		—		—		(204)		—		—		(204)		50		(154)		—		(154)		(0.01)
Stock compensation expense		—		1,742		(12,910)		(591)		—		15,243		—		—		15,243		(3,707)		11,536		—		11,536		0.47
Amortization expense		—		1,179		(31,918)		—		—		33,097		—		—		33,097		(8,160)		24,937		—		24,937		1.01
Restructuring, strategic transaction and integration		—		—		—		—		(13,138)		13,138		—		—		13,138		(3,232)		9,906		—		9,906		0.40
Settlements		—		1,176		(250)		—		—		1,426		—		—		1,426		(349)		1,077		—		1,077		0.04
Quality system and product-related remediation		—		13,797		—		—		—		13,797		—		—		13,797		(3,283)		10,514		—		10,514		0.42
Gain on sale of business		—		—		—		—		—		—		—		(2,969)		(2,969)		727		(2,242)		—		(2,242)		(0.09)
Noncash release of loss on contract provision		—		—		1,076		—		—		(1,076)		359		—		(717)		176		(541)		—		(541)		(0.02)
Tax expense from valuation allowance*		—		—		—		—		—		—		—		—		—		(1,385)		(1,385)		—		(1,385)		(0.06)
Tax expense from equity in earnings of unconsolidated affiliates		—		—		—		—		—		—		—		—		—		(377)		(377)		377		—		—
Adjusted (Non-GAAP)**	$	533,295	$	218,571	$	108,771	$	20,660	$	—	$	89,140	$	(19,449)	$	—	$	70,298	$	(18,882)	$	51,416	$	(1,164)	$	50,252	$	2.03
Adjusted percent of total revenues or (percent of income (loss) before income taxes and equity in earnings of unconsolidated affiliates)				41%		20%		4%		—%		17%	(4)%			—%		13%		26.9%		10%
_______________________ *The Company’s non-GAAP annual effective tax rate is calculated without the tax expense related to the valuation allowance against certain U.S. Federal and State deferred tax assets. The valuation allowance was recorded based on an assessment of available positive and negative evidence, including, predominantly, an estimate that we will be in a three-year cumulative U.S. loss position on a GAAP basis as of September 30, 2025. However, based on the same assessment, including, predominantly, our being, in a three-year cumulative U.S. income position on a non-GAAP basis, which excludes the impact of our non-GAAP adjustments, we concluded that recording a valuation allowance would not have been appropriate for non-GAAP reporting. As a result, the tax expense for the valuation allowance was added back to our calculation of non-GAAP annual effective tax rate. **Amounts may not foot due to rounding.

ICU MEDICAL, INC. AND SUBSIDIARIES Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)(continued) (In thousands, except percentages and per share)
The Company’s U.S. GAAP results for the three months ended September 30, 2024 included special items which impacted the U.S. GAAP measures as follows:
	Total revenues		Gross profit		Selling, general and administrative		Research and development		Restructuring, strategic transaction and integration		Change in fair value of contingent earn-out		(Loss) income from operations		(Loss) income before income taxes		Provision for income taxes		Net (loss) income		Diluted (loss) earnings per share
Reported (GAAP)	$	589,131	$	204,852	$	162,707	$	21,028	$	16,828	$	(3,947)	$	8,236	$	(17,928)	$	(15,055)	$	(32,983)	$	(1.35)
Reported percent of total revenues (or percent of (loss) income before income taxes for benefit (provision) for income taxes)				35%		28%		4%		3%	(1)%			1%	(3)%		(84.0)%		(6)%
Contract manufacturing		(9,063)		—		—		—		—		—		—		—		—		—
Stock compensation expense		—		1,816		(9,287)		(667)		—		—		11,770		11,770		(2,825)		8,945		0.36
Amortization expense		—		692		(33,611)		—		—		—		34,303		34,303		(8,338)		25,965		1.06
Restructuring, strategic transaction and integration		—		—		—		—		(16,828)		—		16,828		16,828		(4,043)		12,785		0.52
Change in fair value of contingent earn-out		—		—		—		—		—		3,947		(3,947)		(3,947)		—		(3,947)		(0.16)
Quality system and product-related remediation		—		7,737		—		—		—		—		7,737		7,737		(1,839)		5,898		0.24
Settlements		—		—		(20)		—						20		20		—		20		—
Tax expense from valuation allowance*		—		—		—		—		—		—		—		—		22,394		22,394		0.91
Earnings per share impact on net loss due to basic versus diluted weighted average shares		—		—		—		—		—		—		—		—		—		—		0.01
Adjusted (Non-GAAP)**	$	580,068	$	215,097	$	119,789	$	20,361	$	—	$	—	$	74,947	$	48,783	$	(9,706)	$	39,077	$	1.59
Adjusted percent of total revenues (or percent of (loss) income before income taxes for benefit (provision) for income taxes)				37%		21%		4%		—%		—%		13%		8%		19.9%		7%
_____________ * The Company’s non-GAAP annual effective tax rate is calculated without the tax expense related to the valuation allowance against certain U.S. Federal and State deferred tax assets. The valuation allowance was recorded based on an assessment of available positive and negative evidence, including, predominantly, an estimate that we will be in a three-year cumulative U.S. loss position on a GAAP basis as of September 30, 2024. However, based on the same assessment, including, predominantly, our being, in a three-year cumulative U.S. income position on a non-GAAP basis, which excludes the impact of our non-GAAP adjustments, we concluded that recording a valuation allowance would not have been appropriate for non-GAAP reporting. As a result, the tax expense for the valuation allowance was added back to our calculation of non-GAAP annual effective tax rate. * Amounts may not foot due to rounding

ICU MEDICAL, INC. AND SUBSIDIARIES Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow (Unaudited) (In thousands)
		Three months ended September 30,						Nine months ended September 30,
		2025			2024			2025			2024
Net cash provided by operating activities		$	56,710			36,097		$	119,248		$	163,841
Purchase of property, plant and equipment			(29,080)			(19,910)			(63,397)			(55,292)
Proceeds from sale of assets			—			3			42			695
Free cash flow		$	27,630		$	16,190		$	55,893		$	109,244

ICU MEDICAL, INC. AND SUBSIDIARIES Fiscal Year 2025 Outlook (Unaudited) (In millions, except per share data)
		Low End of Guidance			High End of Guidance
GAAP net loss		$	(8)		$	—
Non-GAAP adjustments:
Interest, net			82			82
Stock compensation expense			55			55
Depreciation and amortization expense			202			202
Restructuring, strategic transaction and integration			59			59
Settlements			2			2
Quality and regulatory initiatives and remediation			40			40
Gain on sale of business			(45)			(45)
Noncash release of loss on contract provision			(2)			(2)
Gross profit on contract manufacturing			(1)			(1)
Provision for income taxes			11			13
Total non-GAAP adjustments		$	403		$	405
Adjusted EBITDA		$	395		$	405
GAAP loss per share		$	(0.30)		$	—
Non-GAAP adjustments:
Stock compensation expense			2.20			2.20
Amortization expense			5.31			5.31
Restructuring, strategic transaction and integration			2.37			2.37
Settlements			0.06			0.06
Quality and regulatory initiatives and remediation			1.62			1.62
Depreciation expense reduction – assets held for sale classification			(0.17)			(0.17)
Gain on sale of business			(1.80)			(1.80)
Noncash release of loss on contract provision			(0.08)			(0.08)
Gross profit on contract manufacturing			(0.05)			(0.05)
Estimated income tax impact from adjustments			(1.81)			(1.81)
Adjusted earnings per share		$	7.35		$	7.65

CONTACT:
ICU Medical, Inc.
Brian Bonnell, Chief Financial Officer
(949) 366-2183

ICR, Inc.
John Mills, Partner
(646) 277-1254

FAQ

What were ICU Medical's (ICUI) Q3 2025 revenue and gross margin?

Q3 2025 revenue was $537.0M and GAAP gross margin was 37%.

How did ICU Medical's (ICUI) adjusted EPS and adjusted EBITDA perform in Q3 2025?

Adjusted diluted EPS was $2.03 and adjusted EBITDA was $105.9M for Q3 2025.

What FY2025 guidance did ICU Medical (ICUI) update on Nov 6, 2025?

FY2025 guidance updated to GAAP net loss $(8)M–$0M, adjusted EBITDA $395M–$405M, and diluted EPS $7.35–$7.65.

Why did ICU Medical's (ICUI) Vital Care revenue fall in Q3 2025?

Vital Care declined due to the May 1, 2025 disposal of the IV Solutions business, reducing Vital Care revenue by $86.5M in Q3.

Did ICU Medical (ICUI) report a GAAP profit in Q3 2025?

No; ICU Medical reported a GAAP net loss of $(3.4)M in Q3 2025, narrower than prior-year loss of $(33.0)M.

How can investors access ICU Medical's Q3 2025 conference call replay?

The conference call was webcast and is available for replay via the company's investor relations website at www.icumed.com.